<DOC>
	<DOCNO>NCT00734500</DOCNO>
	<brief_summary>This prospective , open-label , single center , pharmacokinetic study anidulafungin infant toddler less 24 month age suspect serious infection . There 24 subject enrol ; receive anidulafungin . Patients receive anidulafungin 3 mg/kg load dose day 1 study receive 1.5 mg/kg every 24 hour study day 2-5.Plasma pharmacokinetics evaluate use limited sample scheme . We hypothesize PK parameter anidulafungin differ observed old child adult .</brief_summary>
	<brief_title>Anidulafungin PK Infants Toddlers</brief_title>
	<detailed_description />
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Anidulafungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Age &lt; 24 month time enrollment Patient must sufficient venous access permit administration study medication Infant toddler suspect serious infection blood culture obtain 48 hour study entry Availability willingness parent/legally authorize representative provide write informed consent . Patients history anaphylaxis attribute echinocandin Any concomitant condition , opinion investigator would preclude patient 's participation study Previous participation study Previous exposure echinocandin month prior study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>